MedTrace Logo

BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL

NCT05370430 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2025-11-20

No results posted yet for this study

Summary

A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)

Conditions

  • Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Interventions

BIOLOGICAL

BAFFR-CAR T cells

First-in-human trial examining the safety and preliminary efficacy of BAFFR-CAR T cells in participants with r/r B-NHL

Sponsors & Collaborators

  • City of Hope Medical Center

    collaborator OTHER

  • PeproMene Bio, Inc.

    lead INDUSTRY

Principal Investigators

  • Elizabeth Budde, MD · City of Hope Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-13
Primary Completion
2027-07-13
Completion
2028-06-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05370430 on ClinicalTrials.gov